TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03465436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: 100 mg administered orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: 400 mg administered PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered for lasmiditan or moxifloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg moxifloxacin administered PO
Study: NCT04038086

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: oral glucose tolerance test
Description: Participants will undergo an 75 gram oral glucose tolerance test. Blood and CSF will be collected in the fasting state before the test and every 30 minutes throughout the test which lasts for 2 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: circadian rhythm
Description: Blood and CSF will be collected five times throughout the day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: effect of insulin on peptide transport
Description: Blood and CSF will be collected in the fasting state and 15, 30, 60, 120 und 240 min after administration of 160 U of human insulin as nasal spray.
Study: NCT00692510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)
Description: Cocktail mix which contains the following:~CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)~single dose of mix

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)
Description: Cocktail mix which contains the following:~CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)~single dose of mix
Study: NCT02182141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 ES
Study: NCT03730194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin (liquid, immediate release, 3 mg) 30 minutes before bedtime

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin (liquid, immediate release, 3 mg) 30 minutes before bedtime

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin (liquid, immediate release, 3 mg) 30 minutes before bedtime

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin (liquid, immediate release, 3 mg) 30 minutes before bedtime

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin (liquid, immediate release, 3 mg) 30 minutes before bedtime

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime Bank
Description: The Bedtime Bank a novel behavioral sleep intervention, which is based upon contingency contracting and relies on a credit or debt-based system to hold adolescents accountable for maintaining a consistent bedtime and improve total sleep time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime Bank
Description: The Bedtime Bank a novel behavioral sleep intervention, which is based upon contingency contracting and relies on a credit or debt-based system to hold adolescents accountable for maintaining a consistent bedtime and improve total sleep time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime Bank
Description: The Bedtime Bank a novel behavioral sleep intervention, which is based upon contingency contracting and relies on a credit or debt-based system to hold adolescents accountable for maintaining a consistent bedtime and improve total sleep time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime Bank
Description: The Bedtime Bank a novel behavioral sleep intervention, which is based upon contingency contracting and relies on a credit or debt-based system to hold adolescents accountable for maintaining a consistent bedtime and improve total sleep time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime Bank
Description: The Bedtime Bank a novel behavioral sleep intervention, which is based upon contingency contracting and relies on a credit or debt-based system to hold adolescents accountable for maintaining a consistent bedtime and improve total sleep time.
Study: NCT03982576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Description: 4 weeks of Transdermal nicotine patches or nicotine gum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy (NRT)
Description: 4 weeks of Transdermal nicotine patches or nicotine gum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CS-CBT intervention
Description: 4 group sessions of a novel culturally specific, CBT-based intervention over 2 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Path2Quit
Description: Path2Quit is a newly developed video-text program, which delivers 6 weeks of CS video messages (1-2 times/day) and provides 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse prevention program
Description: 4 group sessions of a standard relapse prevention program, publicly available at smokefree.gov

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SmokefreeTXT
Description: NCI's 6-week fully automated text-based cessation program that is free to U.S. subscribers, and is available on smokefree.gov. Users can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system 24/7
Study: NCT04314479

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Symptom Assessment and Health Coaching
Description: The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Assessment and Health Coaching
Description: The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes.
Study: NCT00255086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 10mg Memantine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: 10mg placebo pill
Study: NCT02530957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation + High flow nasal cannula oxygen
Description: In the interventional group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% and combined to HNFC (nasal cannula oxygen of Fisher and Paykel) with Flow of 60L/min, FiO2 = 100% is applied.

Intervention type: DEVICE
Group type: OTHER
Intervention: Non invasive ventilation
Description: In the reference group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) only, with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% is applied.
Study: NCT00937794

Intervention type: BEHAVIORAL
Intervention: Neurobehavioral testing
Description: If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to assess his neurodevelopmental status using a standardized battery of neurobehavioral testing.

Intervention type: OTHER
Intervention: Visual and auditory assessments
Description: If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to evaluate his visual and auditory function.
Study: NCT04119427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic therapeutic apparatus 1
Description: After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasonic therapeutic apparatus 2
Description: The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
Study: NCT02208024

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Study: NCT02296437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation combined with cognitive training
Study: NCT02126943

Intervention type: DRUG
Intervention: Opsumit (macitentan)
Description: 10 mg tablets
Study: NCT04117737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality combined with anti-gravity treadmill
Description: The system is composed of three major parts: the treadmill, the antigravity system and the virtual reality system.~The treadmill is the base of the device. It is a rounded and concave structure that permits to walk in all direction. For simulate anti-gravity, a harness and pulley system allow to regulate the weight. Finally, the virtual reality system enables participants to simulate an experience of daily life.
Study: NCT01495338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.17%
Description: 1 drop in one eye at one timepoint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.24% (Formulation 1)
Description: 1 drop in one eye at one timepoint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.24% (Formulation 2)
Description: 1 drop in one eye at one timepoint

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine hydrochloride 0.2%/Tears Naturale II
Description: 1 drop in one eye at one timepoint
Study: NCT02456376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensory Integration Testing
Description: Investigate how sensory information are integrated during upright stance when visual and body senses are challenged in a virtual reality environment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sensory Integration Testing
Description: Investigate how sensory information are integrated during upright stance when visual and body senses are challenged in a virtual reality environment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SR stimulation & Sensory integration testing
Description: Use SR stimulation to improve sensory integration when visual and body senses are challenged in a virtual reality environment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SR stimulation & Sensory integration testing
Description: Use SR stimulation to improve sensory integration when visual and body senses are challenged in a virtual reality environment
Study: NCT02710682

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-open surgery
Description: This treatment will be administered by an orthopedic surgeon specialized in upper limb surgery.~1. Skin disinfection; Local anesthesia (lidocaine 1%).~2. Skin incision, slightly anterior to lateral epicondyle.~3. Exposure of the plane between the tendon and fascia.~4. Extensor Carpi Radialis Longus (ECRL) tendon is lifted to expose the Extensor Carpi Radialis Brevis (ECRB) tendon.~5. Excision of diseased tissue of the ECRB tendon.~6. ECRL tendon is sutured back to the fascia. The skin is closed.~7. Patient is monitored for 30 minutes after procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Tendon fenestration
Description: This treatment will be administered by a fellowship-trained MSK radiologist.~1. Patient's elbow at 70 degrees of flexion with the forearm pronated resting on an examination table.~2. Skin disinfection. Local anesthesia, skin, superficial fascia and tendon, with lidocaine 1%.~3. Using a 22 G needle under continuous ultrasound guidance, several passes (about 20-30) within the abnormal area of the tendon, contacting the bone, until the area softens.~4. Patient monitored for 30 minutes, before being discharged.
Study: NCT00221962

Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole
Description: Open label
Study: NCT01016691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Drug Device
Description: device inserted for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Drug Device
Description: device inserted for 4 days

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Device
Description: device inserted for 4 days
Study: NCT04426500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided transversus abdominus plane block
Description: bilateral TAP using laparoscopic guidance in prostatectomies
Study: NCT00629850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powerlung Performer
Description: Inspiratory/Expiratory muscle trainer
Study: NCT00780299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemodialysis with high permeability (HDHP)
Description: HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVVH
Description: hemofiltration intermittent dialysis
Study: NCT03437850

Intervention type: OTHER
Intervention: Usual care
Description: Care as usual, in terms of processes and outcomes, will be collected for all participants in both cohorts

Intervention type: OTHER
Intervention: Usual care
Description: Care as usual, in terms of processes and outcomes, will be collected for all participants in both cohorts
Study: NCT02699385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Therapy
Description: Each participants will initiate ORT in the physician's office on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Therapy
Description: Each participants will initiate ORT in the physician's office on Day 1.
Study: NCT01981499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05180999
Description: Ascending single oral doses of 120, 240, and 420 mg modified-release tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg MR PF-05180999
Description: Single 120 mg dose administered as modified release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 360 mg MR PF-05180999
Description: Single 360 mg dose administered as modified release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine
Description: Single 10 mg dose of cetirizine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets
Study: NCT01207440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib tablets.
Study: NCT02356991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01405287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTCA with stent placement
Description: PTCA with stent placement (Drug Eluting Stent)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTCA with stent placement
Description: PTCA with stent placement (Drug Eluting Stent)
Study: NCT02447159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfers
Description: Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
Study: NCT03827928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga/meditation
Description: A 6-week yoga and meditation program with psychoeducation components, delivered through community-based yoga sessions. This program offers structured instruction: 10 minutes of breathing exercises to calm the nervous system, 45 minutes of gentle yoga to improve strength, flexibility, and balance, 15 minutes of guided meditation to enhance attention control, emotional regulation, and self-efficacy, and 20 minutes of facilitated discussion with psychoeducation to build community connection and skills in resilience.
Study: NCT01312311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin
Description: Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1
Study: NCT01016691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Description: one drop in each eye on one day only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Description: one drop in each eye on one day only

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 0.03%
Description: one drop in each eye on one day only
Study: NCT03812523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 60 mg qd
Description: 60 mg tablet Taken by mouth, Once Daily for 180 Days
Study: NCT04340778

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inert placebo Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
Study: NCT01842022

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Isomaltulose
Description: Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance
Study: NCT02214420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simeprevir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simeprevir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study: NCT03812523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: 10 mg tablet Taken by mouth Twice Daily for 180 Days
Study: NCT01012557

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Focetria
Description: 7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular)x 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Focetria
Description: 3.75 mcg H1N1v half MF59 adjuvant i.m.(intramuscular)x 1
Study: NCT03905629

Intervention type: OTHER
Intervention: None (retrospective observational study)
Description: This multi-centric retrospective observational cohort study is conducted using the PMSI. Predictive ability of HFRS estimated on the basis of 3 binary outcomes: 30-day in-patient mortality (main outcome), 30-day emergency and potentially avoidable readmission, length of stay \>15 days. Odds ratios (ORs) and c-statistics calculated and compared to the original UK results in order to validate the use of the HFRS in France. Other secondary objectives include:~* Evaluate agreement between HFRS and Charlson or Elixhauser comorbidity indices~* Evaluate ability of HFRS combined with comorbidity indices (Charlson on one hand, and Elixhauser on other hand), to predict 30-day in-patient mortality, 30-day emergency and potentially avoidable readmissions, and long length of stay~* Identify specific risk associations in France of a high risk of frailty (as assessed by the HFRS) with individual, organizational and territorial factors
Study: NCT00796133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NES/E2 gel
Description: Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P\<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
Study: NCT01842022

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Isomaltulose
Description: Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Isomaltulose
Description: Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Isomaltulose
Description: Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance
Study: NCT01012557

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Focetria
Description: 15 mcg N1N1v unadjuvanted i.m.(intramuscular) x 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Focetria
Description: 7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular) x 1